摘要
目的:探讨在含紫杉醇药物化疗过程中,延长对患者的心电监护时间是否更安全和必要。方法:对120例执行含紫杉醇方案化疗的肿瘤患者,用药时进行24h心电监护(常规只监护3h),以每隔3h为一统计时段,分别观察心律失常、心电图异常、低血压发生率和临床症状情况。结果:心律失常(主要是心动过缓)发生率、心电图异常(主要是ST段改变)、低血压现象发生率均呈时间递减,前3h内心律失常26例(21.67%)、ST改变12例(10.00%)、出现低血压28例(23.33%),个别出现相应临床症状,满3h后至24h,心律失常共13例(10.83%)、ST改变10例(8.33%)、发生低血压20例(16.67%)。结论:延长对含紫杉醇药物化疗患者的心电监护具有临床意义,能及时发现24h内心律失常、心电图异常及低血压等并发症,降低医疗风险。
To explore whether more safety and necessity in the course of chemotherapy including paelitaxel in patients with extension of ECG monitoring time. Methods： ECG monitoring for 24 hours（conventional care was only 3 hours） during medication in 120 cases with chemotherapy including paclitaxel, three hours for a statistical interval, the incidence and clinical symptoms of arrhythmia, abnormal electrocardiogram, and hypotension were observed. Results： The incidence of arrhythmia （bradycardia mainly）, abnormal electrocardiogram （ST segment mainly）, hypotension was decreased with time. In the first three hours, there were 26 cases with arrhythmia （21.67%）, 12 cases with ST changes （10.00%）, 28 cases with hypotension （23.33%）, and individual patients with corresponding clinical symptoms. From the third hour to 24 hours, there were a total o{ 13 cases with arrhythmia （10. 83%）, 10 cases with ST changes （8. 33%）, and 20 cases with hypotension （16. 67%）. Conclusion： There were clinical significance in the course of chemotherapy including paclitaxel in pa- tients with extension of ECG monitoring time, It could be found complications such as arrhythmia, ECG abnormality and hypotension within 24 hours in time, and reducing medical risks.
出处
《心血管病防治知识（学术版）》
2011年第2期34-35,共2页
Prevention and Treatment of Cardiovascular Disease
